• news.cision.com/
  • marcus evans/
  • Social Media in Post-Marketing Drug Safety Addressed at the marcus evans 2nd Global Pharmacovigilance & Adverse Event Reporting Conference
English

Social Media in Post-Marketing Drug Safety Addressed at the marcus evans 2nd Global Pharmacovigilance & Adverse Event Reporting Conference

Report this content
Pharmacovigilance Experts Set to Address Drug Safety and Adverse Event Reporting at Two-Day Conference

marcus evans, a conference producing company, will host the 2nd Global Pharmacovigilance & Adverse Event Reporting Conference, May 22-24, 2012 in Boston, MA. More than 16 leading experts will provide insights on dissecting the impact of new global regulations, understanding adverse reporting requirements, strengthening data mining and REMS and deploying signal detection tactics.

PharmaVOICE recently published a cover article in its February 2012 issue titled “Safety and Pharmacovigilance: A Moving Target.” One of the conference speakers, Mr. Patrick Caubel, Vice President, Global Head, Global Pharmacovigilance & Epidemiology at Sanofi, highlights social media as one of his top two challenges.

In the article, Caubel states, “The … challenge is the emergence of diversified and non-conventional sources of safety information—social media—and the need to integrate these data sources into our practice. The public is taking an active role in safety reporting, and partnering within the social world will require total transparency from industry.”

A team of Millennium experts will address this very challenge of integrating and utilizing social media into the overall drug safety plan.  Veronique Kugener, MD, MSc, MBA, Vice President, Pharmacovigilance and Risk Management for Millennium: The Takeda Oncology Company, will lead the session with key aspects including:

  • Leveraging platforms such as YouTube, LinkedIn, twitter and blogging to help promote transparency and education
  • Dissecting the FDA’s draft guidelines regarding social media for the pharmaceutical industry and the potential impact
  • Discussing the future of Adverse Event Reporting (AER) in a digital age with more patients becoming engaged and vocal through numerous platforms
  • Weighing the benefits and legal ramifications of launching an open forum where patients can report positive experiences or adverse reactions

Additional Millennium speakers on the panel include Chris Sanders, Manager, Pharmacovigilance & Risk Management and Pat Connelly, Associate Director, Digital Strategy and Communications.

marcus evans invites Drug Safety, Product Safety and REMS professionals to join in this cutting-edge, peer-to-peer conference that examines best practices in the Pharmacovigilance industry. In addition to two days of conference sessions, attendees will have extensive networking opportunities with their peers.

For more information on this conference or to get a complete list of speakers, sessions or past attendees, visit http://www.marcusevansch.com/PCAR_PR or email Michele Westergaard, Michelew@marcusevansch.com

About marcus evans

marcus evans conferences annually produce over 2,000 high quality events designed to provide key strategic business information, best practice and networking opportunities for senior industry decision-makers. Our global reach is utilized to attract over 30,000 speakers annually, ensuring niche focused subject matter presented directly by practitioners and a diversity of information to assist our clients in adopting best practice in all business disciplines.

Tags:

Pharmacovigilance drug safety REMS adverse event reporting product safety clinical safety signal detection